IMMUNOMODULATORY AGENTS AND PROTEASOME INHIBITORS IN THE TREATMENT OF MULTIPLE MYELOMA

被引：9
|
作者：
Noonan, Kimberly [1 ]
Colson, Kathleen [1 ]
机构：
[1] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA
来源：
SEMINARS IN ONCOLOGY NURSING | 2017年 / 33卷 / 03期
关键词：
multiple myeloma; immunomodulatory drugs; proteasome inhibitors; treatment; side effects; LENALIDOMIDE PLUS DEXAMETHASONE; STEM-CELL TRANSPLANTATION; LOW-DOSE DEXAMETHASONE; NEWLY-DIAGNOSED MYELOMA; LONG-TERM SURVIVAL; ELDERLY-PATIENTS; OPEN-LABEL; CONSENSUS STATEMENT; ANTITUMOR-ACTIVITY; ORAL MELPHALAN;
D O I：
10.1016/j.soncn.2017.05.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OBJECTIVE: To review the current evidence on the use of immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) in the treatment of multiple myeloma (MM). DATA SOURCES: Journal articles, research reports, state of the science papers, and clinical guidelines. CONCLUSION: There has been a tremendous increase of new agents to treat multiple myeloma in the last 15 years. The IMiDs and PIs remain essential components of many anti-myeloma regimens. IMPLICATIONS FOR NURSING PRACTICE: With these advances in the therapeutic landscape, knowledge of these drugs, side effects and nursing implications are essential to improve outcomes. Patient education is also of vital importance in achieving optimal responses to treatment.
引用
下载
收藏
页码：279 / 291
页数：13
相关论文
共 50 条
  • [1] Immunomodulatory Effects of Proteasome Inhibitors in Multiple Myeloma
    Kashiwazaki, Sho
    Kamiko, Satoshi
    Uozaki, Ryo
    Yamamoto, Tomofumi
    Ichikawa, Daiju
    Hattori, Yutaka
    Matsushita, Maiko
    Hirao, Maki
    Kunieda, Hisako
    Yamazaki, Kohei
    BLOOD, 2018, 132
  • [2] Proteasome inhibitors in the treatment of multiple myeloma
    McBride, Ali
    Ryan, Patricia Y.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (03) : 339 - 358
  • [3] Proteasome inhibitors in the treatment of multiple myeloma
    J J Shah
    R Z Orlowski
    Leukemia, 2009, 23 : 1964 - 1979
  • [4] Proteasome Inhibitors for the Treatment of Multiple Myeloma
    Ito, Shigeki
    CANCERS, 2020, 12 (02)
  • [5] Proteasome inhibitors for the treatment of multiple myeloma
    Scalzulli, Emilia
    Grammatico, Sara
    Vozella, Federico
    Petrucci, Maria Teresa
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (04) : 375 - 386
  • [6] Proteasome inhibitors in the treatment of multiple myeloma
    Shah, J. J.
    Orlowski, R. Z.
    LEUKEMIA, 2009, 23 (11) : 1964 - 1979
  • [7] Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma
    Fatemeh Karimi
    Mojtaba Aghaei
    Najmaldin Saki
    Current Treatment Options in Oncology, 2025, 26 (3) : 197 - 212
  • [8] Role of proteasome inhibitors as treatment of multiple myeloma
    Pasquier, Florence
    Moreau, Anne-Sophie
    Tricot, Sabine
    Wemeau, Mathieu
    Facon, Thierry
    Leleu, Xavier
    HEMATOLOGIE, 2006, 12 (01): : 67 - 76
  • [9] New proteasome inhibitors in the treatment of multiple myeloma
    de Moraes Hungria, Vania Tietsche
    Crusoe, Edvan de Queiroz
    Bittencourt, Rosane Isabel
    Maiolino, Angelo
    Pessoa Magalhaes, Roberto Jose
    Sobrinho, Jairo do Nascimento
    Pinto, Jorge Vaz
    Fortes, Ricardo Coutinho
    Moreira, Eloisa de Sa
    Tanaka, Paula Yurie
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2019, 41 (01) : 76 - 83
  • [10] Safety of proteasome inhibitors for treatment of multiple myeloma
    Schlafer, Danielle
    Shah, Katherine S.
    Panjic, Elyse Hall
    Lonial, Sagar
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (02) : 167 - 183
12345